Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
10.56
+0.32 (3.13%)
Apr 1, 2026, 4:00 PM EDT - Market closed
Armata Pharmaceuticals Revenue
In the year 2025, Armata Pharmaceuticals had annual revenue of $4.90M, down -5.22%. Armata Pharmaceuticals had revenue of $1.09M in the quarter ending December 31, 2025, a decrease of -12.15%.
Revenue (ttm)
$4.90M
Revenue Growth
-5.22%
P/S Ratio
78.88
Revenue / Employee
$81,733
Employees
60
Market Cap
386.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.90M | -270.00K | -5.22% |
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 115.00K | -145.00K | -55.77% |
| Dec 31, 2016 | 260.00K | -215.00K | -45.26% |
| Dec 31, 2015 | 475.00K | 66.00K | 16.14% |
| Dec 31, 2014 | 409.00K | 328.00K | 404.94% |
| Dec 31, 2013 | 81.00K | -583.00K | -87.80% |
| Dec 31, 2012 | 664.00K | -8.05M | -92.38% |
| Dec 31, 2008 | 8.72M | -1.61M | -15.62% |
| Dec 31, 2007 | 10.33M | 468.00K | 4.74% |
| Dec 31, 2006 | 9.86M | 2.99M | 43.50% |
| Dec 31, 2005 | 6.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 75.39M |
| Enanta Pharmaceuticals | 66.98M |
| Invivyd | 53.43M |
| XOMA Royalty | 52.15M |
| X4 Pharmaceuticals | 35.11M |
ARMP News
- 7 days ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - PRNewsWire
- 14 days ago - Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ - PRNewsWire